Incyte Corporation is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics, primarily targeting oncology and inflammation. The company's lead product, JAKAFI, is approved for treating myelofibrosis and polycythemia vera, while Iclusig is used for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Incyte is advancing several clinical-stage programs, including treatments for chronic graft-versus-host disease, essential thrombocythemia, and advanced cancers like bladder cancer and follicular lymphoma. The company has also launched dermatology products, such as Opzelura, which is approved for atopic dermatitis and vitiligo. Incyte actively collaborates with various pharmaceutical companies to enhance the development and commercialization of its product pipeline, which is designed to address unmet medical needs. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte aims to deliver innovative therapies to patients worldwide.
BioTheryX, Inc. is a biopharmaceutical company based in Chappaqua, New York, that specializes in the development of therapies for hematological malignancies and other diseases. The company focuses on restoring protein homeostasis through innovative approaches such as Protein Homeostatic Modulators, which are small molecular glue cereblon binders with significant therapeutic potential. Additionally, BioTheryX is advancing targeted protein degradation technologies, including PROTACs, which utilize dual ligands to facilitate the degradation of specific proteins. The company also offers BTX-A51, an oral small molecule that acts as a multi-kinase inhibitor to target leukemic stem cells and suppress key oncogenic gene transcription. Founded in 2007, BioTheryX aims to expedite the delivery of effective therapies to patients with unmet medical needs by leveraging enhanced biology-driven models and clinically proven translational approaches.
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing.
It was established in 1994 and is headquartered in Lexington, Massachusetts.
ARIAD Pharmaceuticals - European operations
Acquisition in 2016
ARIAD Pharmaceuticals - European operations focuses on cancer.
Maxia Pharmaceuticals
Acquisition in 2003
Maxia Pharmaceuticals is a privately-held drug discovery and development company that specialized in small molecule drugs.
Iconix Biosciences provides a toxicogenomics database of microarray and pharmacology data (DrugMatrix®) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures®, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action.
De Novo Pharmaceuticals
Series B in 2001
De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can convert information from structural genomics and medicinal chemistry rapidly into new chemical designs, maximising value within a pharmaceutical partner's research portfolio. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals and NV Organon.
Proteome is a privately held proteomics information company. The company has developed an integrated biological knowledge system to provide researchers with valuable information related to gene and protein function.
GeneEd
Seed Round in 2000
GeneEd is the leading provider of e-Learning solutions for life science, combining advanced web technologies, creative design and educational skills into a productive and compelling learning experience. They take validated content created by domain experts and transform it into accredited multimedia courses including animations with synchronized streaming audio and thoughtfully designed interactive exercises. The courses are viewed in their Webinar™ environment that captures all of the positive attributes of a live seminar but retains the "anytime, any place, any pace" power of the internet. Their catalog courses are delivered using a platform that allows online registration, as well as student testing and tracking for corporate clients.
Synteni
Acquisition in 1998
Synteni is a privately held microarray-based gene expression company. The company specializes in genetic research.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.